Abstract:Background R3HDM1, an RNA binding protein with one R3H domain, remains uncharacterized in terms of its association with tumor progression, malignant cell regulation, and the tumor immune microenvironment. This paper aims to fill this gap by analyzing the potential of R3HDM1 in diagnosis, prognosis, chemotherapy, and immune function across various cancers. Methods Data was collected from the Firehost database ( http://gdac.broadinstitute.org ) to obtain the TCGA pan-cancer queue containing tumor and normal samples. Additional data on miRNA, TCPA, mutations, and clinical information were gathered from the UCSC Xena database ( https://xenabrowser.net/datapages/ ). The mutation frequency and locus of R3HDM1 in the TCGA database were examined using the cBioPortal. External validation through GEO data was conducted to assess the differential expression of R3HDM1 in different cancers. Protein expression levels were evaluated using the Clinical Proteomics Tumor Analysis Alliance (CPTAC). The differential expression of R3HDM1 was verified in lung adenocarcinoma cell lines and normal lung glandular epithelial cells via RT-qPCR. Cell migration and proliferation experiments were conducted by knocking down the expression of R3HDM1 in two lung adenocarcinoma cell lines using small interfering RNA. The biological role of R3HDM1 in pan-cancer was explored using the GSEA method. Multiple immune infiltration algorithms from the TIMER2.0 database was employed to investigate the correlation between R3HDM1 expression and the tumor immune microenvironment. Validation of transcriptome immune infiltration was based on 140 single-cell datasets from the TISCH database. The study also characterized a pan-cancer survival profile and analyzed the differential expression of R3HDM1 in different molecular subtypes. The relationship between R3HDM1 and drug resistance was investigated using four chemotherapy data sources: CellMiner, GDSC, CTRP and PRISM. The impact of chemicals on the expression of R3HDM1 was explored through the CTD database. Result The study revealed differential expression of R3HDM1 in various tumors, indicating its potential as an early diagnostic marker. Changes in somatic copy number (SCNA) and DNA methylation were identified as factors contributing to abnormal expression levels. Additionally, the study found that R3HDM1 expression is associated with clinical features, metabolic pathways, and important pathways related to metastasis and the immune system. High expression of R3HDM1 was linked to poor prognosis across different tumors and altered drug sensitivity. Furthermore, the expression of R3HDM1 showed significant correlations with immune modulatory molecules and biomarkers of lymphocyte subpopulation infiltration. Finally, the study highlighted four chemicals that could influence the expression of R3HDM1. Conclusion Overall, this study proposes that R3HDM1 expression is a promising biomarker for predicting the prognosis of cancer, especially lung adenocarcinoma, and the efficacy of immunotherapy, demonstrating the rationale for further exploration in the development of anti-tumor therapies.

Identification of ACBD3 As a New Molecular Biomarker in Pan-Cancers Through Bioinformatic Analysis: a Preclinical Study

Comprehensive pan-cancer analysis of ACSS3 as a biomarker for prognosis and immunotherapy response

Overexpressed ACBD3 Has Prognostic Value in Human Breast Cancer and Promotes the Self-Renewal Potential of Breast Cancer Cells by Activating the Wnt/beta-catenin Signaling Pathway.

PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer

ACBD3 is up-regulated in gastric cancer and promotes cell cycle G1-to-S transition in an AKT-dependent manner

Cell Division Cycle-Associated Protein 3 (CDCA3) is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer

Pan-cancer analysis identifies CDCA3 as a novel prognostic marker associated with immune infiltration in lung adenocarcinoma through bioinformatics analysis

Integrated Analysis of Expression and Prognostic Values of Acyl-CoA Dehydrogenase Short-Chain in Colorectal Cancer.

LPCAT3 is a potential prognostic biomarker and may be correlated with immune infiltration and ferroptosis in acute myeloid leukemia: a pan-cancer analysis

Pan-cancer analysis of ABCC1 as a potential prognostic and immunological biomarker

Comprehensive pan-cancer analysis and experiments revealed R3HDM1 as a novel predictive biomarker for prognosis and immune therapy response

RETRACTED: Cell Division Cycle-Associated Protein 3 (CDCA3) is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer (retracted Article)

MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial-Mesenchymal Transition (EMT) Pathways

CBX3 Is a Prognostic Biomarker That Is Correlated With Lymphocyte Infiltration in Hepatocellular Carcinoma

Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients

Comprehensive Bioinformatics Analyses of APOBECs Family and Identification of APOBEC3D As the Unfavorable Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

Analysis of Ac3-33 Gene Expression in Multiple Organ Cancer and Adjacent Normal Tissue by Rna in Situ Hybridization

Transcriptomic Profiling Identifies DCBLD2 As a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.

Pan-cancer analysis of DNMT3A as a robust prognostic biomarker to predict the immunotherapy response

Zinc finger C3H1-type containing serves as a novel prognostic biomarker in human pan-cancer

Single-cell and Bulk Sequencing Analysis to Evaluate the Oncogenic Role of PDE3A in Pan-Cancer and Validation in Breast Cancer.